Literature DB >> 12729367

Cisplatin treatment triggers familial Mediterranean fever attacks.

Elias Toubi1, Ruth Gershoni-Baruch, Abraham Kuten.   

Abstract

A 42-year-old familial Mediterranean fever (FMF) patient who was treated with cisplatin-based chemotherapy for adenocarcinoma of the lung developed severe and frequent attacks of FMF during treatment. Abdominal pain, arthralgia and fever occurred for a few days following each cisplatin cycle. His FMF worsened, the abdominal pain and fever lasted longer and treatment with colchicine was ineffective. It has been hypothesized that the link between cisplatin treatment and FMF attacks lies in an increased production of serotonin, IL-6, IL-1, IL-8 and TNF-alpha. These inflammatory cytokines have been reported to be overproduced during cisplatin treatment and are known to play an important role in FMF relapse. The oncologist should be made aware of the possibility of disease aggravation in FMF patients during cisplatin-based chemotherapy.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12729367     DOI: 10.1177/030089160308900116

Source DB:  PubMed          Journal:  Tumori        ISSN: 0300-8916


  3 in total

1.  Selective serotonin reuptake inhibitors in familial Mediterranean fever: are we treating depression or inflammation?

Authors:  Levent Ozçakar; Ahmet Mesut Onat; Semra Ulusoy Kaymak; Kemal Ureten; Ayşen Akinci
Journal:  Rheumatol Int       Date:  2004-09-21       Impact factor: 2.631

2.  NLRP3 inflammasome knockout mice are protected against ischemic but not cisplatin-induced acute kidney injury.

Authors:  Hyun-Jung Kim; Dong Won Lee; Kameswaran Ravichandran; Daniel O Keys; Ali Akcay; Quocan Nguyen; Zhibin He; Alkesh Jani; Danica Ljubanovic; Charles L Edelstein
Journal:  J Pharmacol Exp Ther       Date:  2013-07-05       Impact factor: 4.030

3.  The anti-tumour agent, cisplatin, and its clinically ineffective isomer, transplatin, produce unique gene expression profiles in human cells.

Authors:  Anne M Galea; Vincent Murray
Journal:  Cancer Inform       Date:  2008-06-10
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.